Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: MacroGenics, Inc.

Market Cap 29Cr 25Cr 24Cr 22Cr 41Cr 2.75TCr 42Cr 279.61Cr 108.79Cr 1.35TCr 109.3Cr 106.93Cr 4.7TCr P/E 2026 *
-6.83x
P/E 2027 * -3x
Enterprise Value 29Cr 25Cr 24Cr 22Cr 41Cr 2.75TCr 42Cr 279.61Cr 108.79Cr 1.35TCr 109.3Cr 106.93Cr 4.7TCr EV / Sales 2026 *
1.77x
EV / Sales 2027 * 3.09x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day+10.90%
1 week+10.90%
Current month+10.10%
1 month+1.10%
3 months+60.14%
6 months+188.05%
Current year+184.47%
1 week 3.85
Extreme 3.85
4.6
1 month 3.81
Extreme 3.81
4.64
Current year 1.58
Extreme 1.58
4.64
1 year 1.18
Extreme 1.185
4.64
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
29.16
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
19/05Free

Director

25,750 0.0405%
19/05Free

Director

25,750 0.0405%
19/05Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
+10.90%+10.90%+249.62%-17.48% 29Cr
+0.75%+6.11%+72.10%+120.81% 5.67TCr
+4.00%+7.51%+63.67%+68.77% 4.75TCr
-0.77%-0.67%-15.34%-15.95% 2.28TCr
+2.93%+1.17%-3.97%+384.78% 2.14TCr
+1.30%+3.73%+27.10%-17.51% 1.61TCr
+1.93%+8.32%+24.58%-35.62% 1.56TCr
-1.08%-3.11%+27.20%+158.30% 1.29TCr
+3.30%+15.02%+133.24%+273.89% 1.29TCr
+1.43%-6.44%+21.49% - 1.17TCr
Average +2.47%+3.03%+59.97%+102.22% 2.18TCr
Weighted average by Cap. +1.73%+3.28%+45.38%+110.13%

Financials

2026 *2027 *
Net sales 16Cr 14Cr 13Cr 12Cr 23Cr 1.55TCr 23Cr 157.89Cr 61Cr 763.8Cr 62Cr 60Cr 2.65TCr 9.43Cr 8.24Cr 7.62Cr 7.11Cr 13Cr 890.77Cr 13Cr 91Cr 35Cr 437.96Cr 35Cr 35Cr 1.52TCr
Net income -1.83Cr -1.6Cr -1.48Cr -1.38Cr -2.59Cr -172.99Cr -2.61Cr -18Cr -6.84Cr -85Cr -6.87Cr -6.72Cr -295.46Cr -13Cr -11Cr -10Cr -9.58Cr -18Cr -1.2TCr -18Cr -122.01Cr -47Cr -590.24Cr -48Cr -47Cr -2.05TCr
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
22/26/22 $4.580 +10.90% 20,39,946
18/26/18 $4.130 +4.29% 9,73,000
17/26/17 $3.960 +2.06% 6,49,604
16/26/16 $3.880 -6.05% 5,48,417
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.580USD
Average target price
6.750USD
Spread / Average Target
+47.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!